The pharmacokinetics of piperacillin were examined after single intravenous doses to three groups of male patients with creatinine clearances.of -60 (group I), .20 but <60 (group II), and <20 (group III) ml/min per 1.73 M2. Each of 32 patients received either 1 or 4 g of piperacillin as a bolus injection. Three patients received both doses. After a rapid 0.5-to 1-h distribution phase, antibiotic levels in serum declined monoexponentially. After the 1-g dose, mean peak piperacillin levels in serum were 60, 103, and 67 ,g/ml and the P phase elimination half-lives were 1.0, 1.6, and 3.9 h in groups I, II, and III, respectively. After the 4-g dose, the respective mean peak piperacillin levels in serum were 329, 232, and 262 ,ug/ml and P phase half-lives were 1.4, 2.3, and 2.6 h in the three groups. There was no clear evidence of significant dose-dependent effects on any pharmacokinetic parameters in any of the groups. Piperacillin levels in urine were far higher than those in serum, generally exceeding the minimal inhibitory concentrations for susceptible organisms during the 24 h after both the 1-and the 4-g dose. Piperacillin dosage modification is required only in patients with severe renal impairment.
Piperacillin is a new semisynthetic parenteral penicillin with a broad spectrum of activity against gram-positive and gram-negative organisms (4, 8) . Previous studies on the pharmacokinetics of piperacillin in healthy individuals have shown that it behaves similarly to other penicillins (1, 14) , distributing into an apparent body volume representing 20 to 25% of body weight and having a serum half-life of approximately 1 h. One study has suggested that piperacillin clearance is dose dependent, its half-life in serum increasing as the dose is increased from 1 to 4 g (14) . Similar serum half-lives were obtained after 4-and 6-g doses (12) .
Recent studies have shown that, although 70 to 80o of dosed piperacillin is cleared unchanged via the kidneys, the half-life of the drug in serum increases only moderately to 2 to 3.5 h in patients with severe renal impairment (2, 6, 13) , perhaps owing, partly to a compensating increase in biliary excretion (5) . As piperacillin may be useful in the treatment of some urinary tract infections (11, 12) , it is important to determine the antibiotic levels obtained in patients with various degrees of renal function and&urine output. This information does not appear to be presently available. The study described in this report was designed (i) to provide a more general description of piperacillin pharmacokinetics in patients with a wider cross-section of renal function than has hitherto been available, (ii) to examine the possible dose dependency of piperacillin pharmacokinetics, and (iii) to determine piperacillin concentrations in urine during the 24 h after the administration of 1-and 4-g doses to patients with normal, moderately impaired, and severely impaired r,enal functions.
For logistical reasons, it was not possible in most cases to administer the two different piperacillin doses to the same patients; however, three patients with severe renal impairment received both the 1-and the 4-g dose.
MATERIALS AND METHODS
Subjects. Thirty-two hospitalized male patients suffering from a variety of diseases participated in the study. Subjects were restricted to their wards but were not necessarily at bed rest.
Before participating, all subjects underwent a physical examination including urinalysis, hematology, blood chemistry, and drug history. Data analyss. The decline in individual serum piperacillin proffles was biexponential, and the data were analyzed by the following equation:
where C is the concentration of piperacillin at t hours after injection, A and B are the intercepts, and a and 1B are first-order rate constants. As the injection time of 2 min was short compared with the duration of the a phase (30 min to 1 h) of the serum proffles, it was considered negligible. Equation 1 is consistent with the pharmacokinetic two-compartment open model, so that analysis was extended to include estimation of the microscopic rate constants, by the following equation: following equation:
(2) and also distribution parameters associated with this model (15) . Estimates of pharmacokinetic parameters were obtained by nonlinear regression analysis on a Univac digital computer (7) . Piperacillin copcentrations were weighted by their reciprocals during computer-fitting procedures.
Areas under piperacillin serum profiles from zero to infinite time were calculated by trapezoidal rule with end correction. Renal clearances were calculated as mean values from 2 to 4, 4 to 6, 6 to 12, and 12 to 24 h postdose urine collections. Serum and urine values and some pharmacokinetic constants were compared by analysis of variance, and significant group or dose effects were further examined by t test, as described previously (3).
RESULTS
Mean piperacillin serum profiles during the 12-h period after the 1-and 4-g doses are shown in Fig. 1 and 2 . After the 1-g dose, mean peak piperacillin levels in serum were 60, 103, and 67 p.g/ml in groups I, II, and III, respectively. Drug levels declined rapidly until 0.5 to 1 h postdose and subsequently at a slower, monoexponential rate. In group I and II subjects, drug was essentially cleared from serum at 12 h. In group III subjects, the mean serum level was 2.5 .ig/ml at 12 h and <1 ,ug/ml (data not shown) at 24 h. After the 4-g dose, mean peak piperacillin levels in serum were 329, 232, and 262 ,ug/ml in groups I, II, and III, respectively. Drug levels then declined rapidly to approximately 100 ,ug/ml at 0.5 to 1 h in all three groups and then at a slower, monoexponential rate, to reach mean levels of 2, 3, and 11 ,ug/ml at 12 h. The piperacillin level in serum at 24 h was 4.5 ,ug/ml in group III but was reduced to negligible levels in the other two groups.
Mean piperacillin concentrations in urine during each collection interval are given in Table 2 . Although they were variable, levels of antibiotic activity in urine were generally many times higher than those in serum in all three subject groups and, in most cases, exceeded the minimal inhibitory concentrations for susceptible organisms up to 12 to 24 h postdosing (4, 8) . Piperacillin levels in urine were similar in group I and II subjects, although they tended to be higher in group II than in group I during the 6-to 12-h and 12-to 24-h collections after the 1-g dose. In group III, mean antibiotic levels in urine were approximately 40%o of those in group I until 6 h postdose but increased to 44 to 57% during the 6-to 12-h group, but the differences were not significant. A similar nonsignificant trend was observed in the elimination half-life in groups I and II, but there was no dose effect for this parameter in group III. On the other hand, the elimination half-life significantly increased in the group order I < II < III (P < 0.05) after both the 4-and the 2-g dose. Both serum and renal clearances after the 1-g dose were significantly larger (P < 0.05) than those after the 4-g dose in group I, but there were no dose effects within the other groups. Renal clearance of piperacillin was significantly reduced in group III subjects as compared with other groups at both dose levels. Serum clearance was significantly larger in group I than in the other groups after the 1-g dose, but there were no significant group effects in this parameter after the 4-g dose.
The relationships between piperacillin elimination and renal function for all subjects and both drug doses are shown in Fig. 3 . Despite only moderate influence of renal function on piperacillin kinetics, significant correlations were obtained between creatinine clearance and the piperacillin elimination rate constant 1, renal clearance, and serum clearance. The correlation coefficient for 13, 0.78, was higher than those for renal and serum clearances, and there was considerable intersubject variation for the latter two parameters. A high correlation was also obtained between the piperacillin elimination halflife and serum creatinine when this relationship was expressed as a power function of the form y = axb. This type of nonlinear relationship has been described previously (9) and is expected for a drug which is eliminated partly by extrarenal routes.
DISCUSSION
The overall relationship between piperacillin pharmacokinetics obtained in this study are in close agreement with that found in previous reports (2, 6, 13) and confirms that, unlike the closely related compounds carbenicillin and ticarcillin, piperacillin elimination is not markedly affected by renal function. The reason that declining renal function has such a small effect on piperacillin kinetics has not been explained by previous studies or by the present results; however, piperacillin is known to concentrate in bile (5, 10) , and this may provide an alternate route of elimination in uremia.
Although the mean recovery of piperacillin in urine was markedly reduced from ca. 70% in patients with normal renal function to ca. 13 to 20% in patients with severe renal impairment, the antibiotic concentration in urine was high in all individuals capable of producing urine. After the 1-g dose, piperacillin levels in urine exceeded 100 ,ug/ml in most patients in group I and II and in some patients in group III up to 12 h postdose. After the 4-g dose, average piperacillin levels remained in excess of 100 Fg/ml even during the 12-to 24-h sampling period in all three groups. In vitro studies have shown piperacillin to be effective against most urinary tract pathogens at drug concentrations ranging from 0.1 to 25 ,ug/ml (4, 11) , so that adequate treatment of urinary tract infections requiring this type of medication may be obtained even in cases of impaired renal function.
The lack of effect of different renal statuses on piperacillin distribution characteristics indicates that penetration of this antibiotic into tissue and the relationship between circulating drug levels and those in extravascular tissues and fluids are similar in individuals with normal and impaired renal function.
The elimination half-life of piperacillin was somewhat prolonged after the 4-g dose as compared with the 1-g dose in groups I and II, but the differences did not reach the 95% significance level. The piperacillin half-life was independent of dose in group III subjects. Of the three individuals in group III who received both doses, two yielded longer piperacillin half-lives after the 4-g dose, whereas the other showed the reverse effect. Our data therefore do not entirely support the previous suggestion that piperacillin elimination is dose dependent (14) . Any differences observed in this study are unlikely to be clinically important.
The results of this study confirm that the elimination of piperacillin, unlike those of carbenicillin and ticarcillin, is affected only to a small extent by different renal functions. In addition, they have shown that, even in patients with marked renal impairment, antibiotic levels in urine are adequate to inhibit most urinary tract pathogens, and this effect may extend through 24 h after a 4-g dose. Any dose-dependent effects on piperacillin elimination are unlikely to be clinically important.
Piperacillin dosage modification is necessary only in patients with severe renal impairment. A single doubling of the usual dosage interval, i.e., from 4 to 6 h to 8 to 12 h, in such patients would provide trough antibiotic levels similar to those observed in patients with normal renal fiYnction.
